The Patent Finder

Activatable INTERLEUKIN-2 Polypeptides

Werewolf Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application PCT/US2019/032321, filed May 14, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 10,696,724Activatable INTERLEUKIN-2 Polypeptides
In force
 · High confidence
UsedRemaining
EMD Serono, Inc.In forceHigh confidence
US 11,352,403Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof
In force
 · High confidence
EMD Serono, Inc.In forceHigh confidence
US 11,535,658Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof
In force
 · Medium confidence
EMD Serono, Inc.In forceMedium confidence
US 12,534,505Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof
In force
 · Medium confidence
EMD Serono, Inc.In forceMedium confidence
US 11,981,716Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof
In force
 · Medium confidence
EMD Serono, Inc.In forceMedium confidence
Application 19/423,455Activatable INTERLEUKIN-2 Polypeptides and Methods of Use Thereof
Pending
Not granted
EMD Serono, Inc.PendingNot granted
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Werewolf Therapeutics, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited